Establishment of Safety Monitoring System for Vaccines Not Included in the National Immunization Program in Korea.

Monitoring Non-NIP Safety Surveillance Vaccines

Journal

Journal of Korean medical science
ISSN: 1598-6357
Titre abrégé: J Korean Med Sci
Pays: Korea (South)
ID NLM: 8703518

Informations de publication

Date de publication:
05 Feb 2024
Historique:
received: 21 08 2023
accepted: 28 11 2023
medline: 6 2 2024
pubmed: 6 2 2024
entrez: 6 2 2024
Statut: epublish

Résumé

In Korea, there are no surveillance programs for vaccines that are not included in the national immunization program (NIP), and vaccine safety monitoring in the adult population is inadequate. This study aimed to establish a safety monitoring system for non-NIP vaccines in adults. Frequently administered non-NIP vaccines were selected. Individuals were included if they received at least one of the selected vaccines at a participating institution and provided informed consent. Solicited and unsolicited adverse events were monitored using questionnaires sent through text messages on days 1, 3, 7, 28, and 90 post-vaccination. Selected adverse events of special interest (AESIs) were monitored monthly by retrospective review of electronic medical records. Causality was assessed according to the Korea Disease Control and Prevention Agency guidelines. Four vaccines (tetanus-diphtheria-pertussis [Tdap], pneumococcal conjugate 13-valent [PCV13], live zoster vaccine [ZVL], and recombinant zoster vaccine [RZV]) were selected, and their safety profiles were monitored at four tertiary hospitals and 10 primary care clinics. The response rates of the questionnaires on post-vaccination days 1, 7, 28, and 90 were 99.2%, 93.6%, 81.0%, and 48.7%, respectively. Of 555 AESI identified over 10 months, 10 cases received one of the selected non-NIP vaccines within 90 days of the event. We are establishing the first safety monitoring system for selected non-NIP vaccines in Korea since September 2022 and report its progress as of July 2023. However, continuous government support is essential for its maintenance and improvement.

Sections du résumé

BACKGROUND BACKGROUND
In Korea, there are no surveillance programs for vaccines that are not included in the national immunization program (NIP), and vaccine safety monitoring in the adult population is inadequate. This study aimed to establish a safety monitoring system for non-NIP vaccines in adults.
METHODS METHODS
Frequently administered non-NIP vaccines were selected. Individuals were included if they received at least one of the selected vaccines at a participating institution and provided informed consent. Solicited and unsolicited adverse events were monitored using questionnaires sent through text messages on days 1, 3, 7, 28, and 90 post-vaccination. Selected adverse events of special interest (AESIs) were monitored monthly by retrospective review of electronic medical records. Causality was assessed according to the Korea Disease Control and Prevention Agency guidelines.
RESULTS RESULTS
Four vaccines (tetanus-diphtheria-pertussis [Tdap], pneumococcal conjugate 13-valent [PCV13], live zoster vaccine [ZVL], and recombinant zoster vaccine [RZV]) were selected, and their safety profiles were monitored at four tertiary hospitals and 10 primary care clinics. The response rates of the questionnaires on post-vaccination days 1, 7, 28, and 90 were 99.2%, 93.6%, 81.0%, and 48.7%, respectively. Of 555 AESI identified over 10 months, 10 cases received one of the selected non-NIP vaccines within 90 days of the event.
CONCLUSION CONCLUSIONS
We are establishing the first safety monitoring system for selected non-NIP vaccines in Korea since September 2022 and report its progress as of July 2023. However, continuous government support is essential for its maintenance and improvement.

Identifiants

pubmed: 38317446
pii: 39.e45
doi: 10.3346/jkms.2024.39.e45
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e45

Subventions

Organisme : Ministry of Food and Drug Safety
ID : 22183MFDS435
Pays : Korea

Informations de copyright

© 2024 The Korean Academy of Medical Sciences.

Déclaration de conflit d'intérêts

The authors have no potential conflicts of interest to disclose.

Auteurs

Eliel Nham (E)

Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea.

Jin Gu Yoon (JG)

Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea.

Min Joo Choi (MJ)

Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea.

Yu Bin Seo (YB)

Division of Infectious Diseases, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.

Jacob Lee (J)

Division of Infectious Diseases, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.

Won Suk Choi (WS)

Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea.

Hakjun Hyun (H)

Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea.

Hye Seong (H)

Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea.

Ji Yun Noh (JY)

Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea.

Joon Young Song (JY)

Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea.

Woo Joo Kim (WJ)

Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea.

Hee Jin Cheong (HJ)

Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea. heejinmd@korea.ac.kr.

Classifications MeSH